Back
Invesco FTSE RAFI Dev Mkts ex-US ETF Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
42
PXF
Invesco FTSE RAFI Dev Mkts ex-US ETF
Last Price:
48.75
Seasonality Move:
1%
Buy
51
ALNY
Alnylam Pharmaceuticals
Last Price:
242.97
Seasonality Move:
20.36%
Sell
42
Invesco FTSE RAFI Dev Mkts ex-US ETF (PXF)
is a Sell
Is Invesco FTSE RAFI Dev Mkts ex-US ETF a Buy, Sell or Hold?
- The current Invesco FTSE RAFI Dev Mkts ex-US ETF [PXF] share price is $48.68. The Score for PXF is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.
- PXF is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
51
Alnylam Pharmaceuticals (ALNY)
is a Buy
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $243.08. The Score for ALNY is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
- ALNY is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
PXF Stock Price Chart
What is Invesco FTSE RAFI Dev Mkts ex-US ETF's stock price today?
-
The Invesco FTSE RAFI Dev Mkts ex-US ETF share price today is $48.68
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and PXF is experiencing slight selling pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $243.08
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
PXF Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.4 | Sell |
| Relative Strength Index (14 RSI): | 38.56 | Sell |
| Chaikin Money Flow: | -20963 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (48.91 - 50.55) | Sell |
| Bollinger Bands (100): | (47.89 - 50.25) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 22.91 | Buy |
| Relative Strength Index (14 RSI): | 86.77 | Buy |
| Chaikin Money Flow: | -1210062 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (135.8 - 205.74) | Buy |
| Bollinger Bands (100): | (136.44 - 176.64) | Buy |
PXF Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 48.83 | Sell |
| 20-day SMA: | 49.57 | Sell |
| 50-day SMA: | 49.7 | Sell |
| 200-day SMA: | 47.02 | Buy |
| 8-day EMA: | 48.85 | Sell |
| 20-day EMA: | 49.32 | Sell |
| 50-day EMA: | 49.47 | Sell |
| 200-day EMA: | 47.66 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 209.44 | Buy |
| 20-day SMA: | 176.25 | Buy |
| 50-day SMA: | 159.62 | Buy |
| 200-day SMA: | 165.96 | Buy |
| 8-day EMA: | 218.01 | Buy |
| 20-day EMA: | 188.75 | Buy |
| 50-day EMA: | 168.9 | Buy |
| 200-day EMA: | 168.09 | Buy |
Invesco FTSE RAFI Dev Mkts ex-US ETF Earnings Growth & PXF Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.12 per share, a decrease this year of $0.46 per share, and an increase next year of $1.83 per share.
Invesco FTSE RAFI Dev Mkts ex-US ETF Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||